Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70

N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes

(2015) Y. Wang et al.   CHEMICAL COMMUNICATIONS

Chemically Accessible Hsp90 Inhibitor That Does Not Induce a Heat Shock Response

(2014) Yen Chin Koay et al.   ACS Medicinal Chemistry Letters

A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response

(2013) Jeanette R. McConnell et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

(2013) Jonathan W Goldman et al.   BMC CANCER

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

(2013) Shanu Modi et al.   BREAST CANCER RESEARCH AND TREATMENT

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

(2013) M Beloueche-Babari et al.   BRITISH JOURNAL OF CANCER

Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells

(2013) Nishant Gandhi et al.   CANCER BIOLOGY & THERAPY

HSF1 in Translation

(2013) Emmanuel de Billy et al.   CANCER CELL

Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors

(2013) Håkon Reikvam et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma

(2013) M. Chatterjee et al.   HAEMATOLOGICA

Dynamic Impacts of the Inhibition of the Molecular Chaperone Hsp90 on the T-Cell Proteome Have Implications for Anti-Cancer Therapy

(2013) Ivo Fierro-Monti et al.   PLoS One

Inhibition of HSP70: A challenging anti-cancer strategy

(2012) Anastasia R. Goloudina et al.   CANCER LETTERS

Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition

(2012) Mikko Taipale et al.   CELL

Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution

(2012) L. Whitesell et al.   CURRENT MOLECULAR MEDICINE

Macrocycles That Inhibit the Binding between Heat Shock Protein 90 and TPR-Containing Proteins

(2011) Veronica C. Ardi et al.   ACS Chemical Biology

Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90

(2011) Joseph B. Kunicki et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone?

(2011) Marissa V. Powers et al.   CELL CYCLE

Design and synthesis of Hsp90 inhibitors: Exploring the SAR of Sansalvamide A derivatives

(2010) Robert P. Sellers et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Heat Shock Protein 70 (Hsp70) as an Emerging Drug Target

(2010) Christopher G. Evans et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma

(2010) E L Davenport et al.   LEUKEMIA

Targeting HSP90 for cancer therapy

(2009) D Mahalingam et al.   BRITISH JOURNAL OF CANCER

A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells

(2009) Andrew J. Massey et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY